Beneficial effects of Wy14643, an agonist for peroxisome proliferator-activated receptor (PPAR)α, on permeability bar- 
study demonstrated that Wy14643 reduced the expression of thymus and activation-related chemokine (TARC) and regulated on activation normal T cell expressed (RANTES) in both single-and 3D-cultured human keratinocytes. The combined data of the present and previous studies support the notion that Wy14643 could be a therapeutic agent that might simultaneously and directly modulate permeability barrier dysfunction and allergic inflammation in the pathogenesis of atopic dermatitis. As for the anti-microbial barrier function, the present study demonstrated that Wy14643 up-regulated expression of the anti-microbial peptide, human β defensin 3, in cultured human keratinocytes only in mRNA levels but not in protein ones, suggesting that Wy14643 might not directly account for the up-regulation of the anti-microbial peptide which has been reported in vivo.
| BACKGROUND
Permeability barrier dysfunction, antimicrobial dysfunction and allergic inflammation are the principal pathogenic features of atopic dermatitis (AD). [1] Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are classified into three subclasses: PPARα, PPARβ/δ and PPARγ. [2] Reduced expression of PPARα (but not of PPARβ/δ or PPARγ) in human atopic dermatitis (AD) lesions and epidermis in hapten-induced AD-like dermatitis has been reported. [3, 4] In addition, PPARα-deficient mice show a more severe hapten-induced AD-like dermatitis than wild-type mice. [3] These data suggest that reduction in PPARα might be involved in the pathogenesis of AD. Consistent with these data, we demonstrated that decreased PPARα not only downregulated the expression of epidermal differentiation-related molecules but also upregulated the expression of thymus and activation-related chemokine (TARC) and regulated on activation normal T cell expressed (RANTES) in cultured human keratinocytes. [5] TARC and RANTES are chemokines produced by keratinocytes that are important in terms of cutaneous inflammation of AD. [6, 7] Therefore, these results suggest that PPARα in keratinocytes might play a role in both permeability barrier dysfunc- ed. [8, 9] However, effects of PPARα agonists on allergic inflammationrelated functions in keratinocytes have not been addressed.
| QUESTIONS ADDRESSED
The present study addressed whether the synthetic PPARα ligand, Wy14643, could influence inflammatory functions (ie expression of chemokines such as TARC and RANTES) of keratinocytes to modulate the cutaneous allergic inflammation of AD. In addition, the present study addressed whether Wy14643, similar to other previously reported PPARα ligands, could augment antimicrobial barrier functions of keratinocytes. Based on our results, we consider that Wy14643 might be a therapeutic agent that modulates not only the already known skin barrier functions, such as the permeability barrier and the antimicrobial barrier, but that might also simultaneously and directly modulate cutaneous allergic inflammation in AD.
| EXP. DESIGN
We examined the effects of Wy14643 (Sigma, St. Louis, MO) on the expression of TARC and RANTES in cultured human keratinocytes using both single-layer and 3D cell culture systems. Expression levels of these molecules were evaluated by analysis of their mRNA levels in cultured keratinocytes and their protein levels in the culture supernatant using quantitative RT-PCR and ELISA, respectively. The effects of Wy14643 on the expression of the antimicrobial peptide, human β-defensin-3 (hBD3) in cultured human keratinocytes, were also examined.
Cell culture, cell stimulation, RT-PCR, ELISA and statistical analysis were performed as described in the Data S1.
| RESULTS
Wy14643 downregulated the mRNA expression, and the protein level in the culture supernatant, of both TARC and RANTES not only in single-layer-cultured keratinocytes ( Figure 1 ) but also in 3D-cultured keratinocytes ( Figure 2 ). In contrast, the mRNA expression of hBD3 was upregulated by Wy14643 in both single-layer-cultured and 3D-cultured keratinocytes (Fig. S1 ). Meanwhile, there was no difference in the protein level of hBD3 in culture supernatant in 3D-cultured keratinocytes between with and without Wy14643 (Fig. S1 ). The protein of hBD3 was not detected in culture supernatant in singlelayer-cultured keratinocytes (data not shown).
| CONCLUSIONS
The present study demonstrated that an agonist for PPARα could suppress the expression of TARC and RANTES that are known to be involved in the pathogenesis of AD in cultured keratinocytes.
These results might explain part of the mechanism of the therapeutic effects of topical treatments with PPARα agonists in AD-like dermatitis induced by hapten application in murine models. [4, 10] Antiinflammatory effects of agonists for PPARα have been demonstrated in cutaneous inflammatory models, and an antigen-presenting cell, the Langerhans cell, was reported to be a target cell for the antiinflammatory effects of agonists for PPARα. [2] The present study is the first to demonstrate that keratinocytes could be a target cell in the anti-inflammatory effects of ligands for PPARα and the results support the previously reported regulatory effects of PPARα signalling on the inflammatory functions of keratinocytes (ie expression of TARC and RANTES). [5] Beneficial effects of agonists for PPARα including Wy14643 on the permeability barrier homeostasis-related functions of keratinocytes have been demonstrated. [8] In addition, the present study demonstrated that Wy14643, as was reported for another ligand for PPARα, GW9578, [9] upregulated the mRNA expression of hBD3 in cultured 
